1. The combination of a) a compound of formula Ia: or a pharmaceutically acceptable salt thereof； and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylaxis or therapeutic treatment of hyperproliferative disorder. 2. The combination according to claim 1, where the hyperproliferative disorder is a malignant neoplasm. The combination according to claim 2, where the malignant neoplasm is associated with a PTEN mutation. The combination of claim 2, wherein the malignant neoplasm is associated with an AKT mutation, overexpression, or amplification. The combination according to claim 2, where the malignant neoplasm is associated with a PI3K.6 mutation. The combination according to claim 2, where the malignant neoplasm is associated with the amplification of Her2 / ErbB2.7. The combination according to any one of claims 2 to 6, wherein the cancer is selected from breast cancer, lung cancer, ovarian cancer, prostate cancer, melanoma, gastric cancer, colon cancer, kidney cancer, head cancer and neck cancer, and glioma. 8. The combination according to any one of claims 1 to 6, wherein the combination provides a synergistic effect in the treatment of hyperproliferative disorder. The combination of claim 8, where the value of the combinatorial index of the synergistic effect is less than about 0.8.10. The combination according to claim 7, where the combination provides a synergistic effect in the treatment of hyperproliferative disorders. A compound of formula Ia or a pharmaceutically acceptable salt thereof, as defined in claim 1, for therapeutic use to improve the quality of life of a patient who is being treated for a hyperproliferative disorder with erlotinib or a pharmaceutically acceptable salt thereof. A method for treating a hyperproliferative disease in a mammal, comprising administering to a mammal1. Комбинация a) соединения формулы Ia:или его фармацевтически приемлемой соли； и b) эрлотиниба или его фармацевтически приемлемой соли для профилакт
